hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06334926, orgStudyIdInfo id: EK 18-002-VK, briefTitle: BMI and Lymph Node Count in Colorectal Cancer, statusModule overallStatus: COMPLETED, startDateStruct date: 2017-12-01, primaryCompletionDateStruct date: 2020-03-31, completionDateStruct date: 2020-03-31, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Klinikum Floridsdorf, class: OTHER, collaborators name: Medical University of Vienna, collaborators name: Klinik Favoriten, collaborators name: Salzkammergut Klinikum Vöcklabruck, descriptionModule briefSummary: Background and aim: Colorectal Cancer (CRC) is one of the most frequent cancer entities in the western world. It is known that obesity is one of the major risk factors for CRC. In contrast, mild obesity seems to have a positive effect on postoperative outcome, which is known as the "obesity paradox". Also, the number of resected lymph nodes (LN) during surgery is very important for correct staging. The aim of the present project is to evaluate the impact of BMI and LN-yield on long term overall survival (OS) of CRC patients treated with curative intent.Methods: Patients treated for CRC between 1998 and 2011 at the Klinik Favoriten in Vienna, Austria were analyzed in this retrospective single-center cohort analysis concerning OS., conditionsModule conditions: The Aim of This Study is to Determine the Influence of BMI and Lymph Node Status on OS in CRC Patients in the Long Term, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: OTHER, enrollmentInfo count: 1192, type: ACTUAL, armsInterventionsModule interventions name: no intervention, retrospective data analysis, outcomesModule primaryOutcomes measure: overall survival, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Klinik Floridsdorf, city: Wien, zip: 1210, country: Austria, geoPoint lat: 48.20849, lon: 16.37208, hasResults: False
protocolSection identificationModule nctId: NCT06334913, orgStudyIdInfo id: IRAS 332286, briefTitle: A Prospective Patient Reported Outcomes and Wearables Study in Myeloproliferative Neoplasms, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2029-04-01, completionDateStruct date: 2029-04-01, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Guy's and St Thomas' NHS Foundation Trust, class: OTHER, descriptionModule briefSummary: The investigators will assess the use of a smart phone app to monitor patient reported outcomes and record biometric data in patients with myeloproliferative neoplasms., conditionsModule conditions: Myeloproliferative Neoplasm, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 1000, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Patient reported outcomes - Myeloproliferative Neoplasm-10 Total Symptom Score, secondaryOutcomes measure: Healthcare adherence, secondaryOutcomes measure: Biometric data analysis - activity index, secondaryOutcomes measure: Biometric data analysis - sleep score, secondaryOutcomes measure: Biometric data analysis - heart rate, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06334900, orgStudyIdInfo id: 69HCL24_0297, briefTitle: Retrospective Analysis of the French National Cohort of Patients With GAD Antibodies and Cerebellar Ataxia, acronym: Ata-GAD, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-01, primaryCompletionDateStruct date: 2024-01-01, completionDateStruct date: 2024-06-30, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Hospices Civils de Lyon, class: OTHER, descriptionModule briefSummary: Glutamic acid decarboxylase (GAD) is an enzyme whose function in the body is to decarboxylate glutamate to GABA. GAD65 antibodies (GAD65Ab) have been associated with type-1 diabetes (80% of new-onset patients) and various neurological conditions, mainly stiff-person syndrome (SPS/PERM), cerebellar ataxia (CA), limbic encephalitis (LE) and temporal lobe epilepsy. These syndromes all seem to result from a reduced transmission of GABA. These neurological conditions are rare and can cause symptoms like confusion, memory loss, muscle stiffness, muscle spasms, behavioural disorders, and pharmacoresistant epilepsy. When finding high levels of GAD65-Ab in the serum, a cerebrospinal fluid (CSF) sample should be taken to look for oligoclonal IgG bands and intrathecal GAD-Ab production to prove an auto-immune cause for the various neurological symptoms., conditionsModule conditions: GAD-receptor Antibodies-associated Encephalitis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: GAD patients, outcomesModule primaryOutcomes measure: GAD Patient, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hôpital Neurologique Pierre Wertheimer / Groupement Hospitalier Est, status: RECRUITING, city: Bron, zip: 69677, country: France, contacts name: Jérôme Honnorat, professor, role: CONTACT, phone: +33 4 72 35 78 06, email: jerome.honnorat@chu-lyon.fr, geoPoint lat: 45.73333, lon: 4.91667, hasResults: False
protocolSection identificationModule nctId: NCT06334874, orgStudyIdInfo id: REC-FPFUE-32/2023, briefTitle: Study of the Efficacy and Safety of Antioxidants Astaxanthin as an Adjuvant Therapy for Community Acquired Pneumonia Patients., statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-07-01, completionDateStruct date: 2024-08-01, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Future University in Egypt, class: OTHER, descriptionModule briefSummary: Community acquired pneumonia (CAP) is one of the most common and morbid conditions encountered in clinical practice, which causes serious morbidity worldwide. In CAP, oxidative stress is linked to inflammation, demonstrated by increased production of interleukin (IL)-6 and tumor necrosis factor (TNF)-α, which attract inflammatory cells and increase oxidant production by these cells. Attenuation of oxidative stress via antioxidants would be expected to result in reduced pulmonary damage. Antioxidants have been found to be effective in alleviating lung injury and protecting against damage of other organs., conditionsModule conditions: Community-acquired Pneumonia, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Astaxanthin Oral Capsule, interventions name: Placebo, outcomesModule primaryOutcomes measure: change in IL-6 after treatment in the ASX group compared with those in the control group., primaryOutcomes measure: change in IL-10 after treatment in the ASX group compared with those in the control group., primaryOutcomes measure: change in tumor necrosis alpha after treatment in the ASX group compared with those in the control group., secondaryOutcomes measure: difference in CURB 65 scores after treatment in the ASX group compared with the control group., secondaryOutcomes measure: o Adverse drug reactions related to ASX as increase bowel movement, stomach pain and increase PT and APTT will be assessed., secondaryOutcomes measure: Length of hospital and ICU stay., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Elmatarya Teaching Hospital, status: RECRUITING, city: Cairo, zip: 4650201, country: Egypt, contacts name: fatma makram, role: CONTACT, phone: 01015000329, email: fatma.aboelhassan@fue.edu.eg, contacts name: eman elmokadam, role: CONTACT, email: Eman.abdellatif@fue.edu.eg, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06334861, orgStudyIdInfo id: 5001, briefTitle: Multidisciplinary Hospital-Territory Vaccine Center: a Model for Achieving the Herpes Zoster Vaccine Coverage, acronym: CeVOT-Her-Zo, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-06-23, primaryCompletionDateStruct date: 2024-05-15, completionDateStruct date: 2024-06-30, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS, class: OTHER, descriptionModule briefSummary: The National Vaccination Program, updated by the Ministry of Health in 2021, provides a new vaccination opportunity for frail patients against Herpes zoster virus (HZ). The new treatment option, on the other hand, is designed by combining VZV-specific antigen (gE) with an adjuvant system (AS01B) to induce antigen-specific cellular and humoral immune responses in individuals with preexisting immunity to VZV. Efficacy, assessed in people given two doses 2 months apart, is around 97% in those aged 50 years and 91% in those over 70 years. In the studies conducted, HZ-related hospitalizations were significantly reduced. The vaccine schedule calls for the administration of two doses 2 months apart. The current HZ Vaccination Program implemented at the regional level recommends its active and free offer in people from 18 years of age with congenital and/or acquired immunodepression, through a collaborative relationship involving, on the one hand, multispecialist and multiprofessional medical staff and, on the other hand, citizens called to play a role that is no longer passive but the subject of empowerment by consciously making their own health choices. The collaboration with ASL Roma1, in this sense, acquires value as guarantor of the supply of the adjuvanted recombinant anti-HZ vaccine and of the appropriate reporting of vaccination coverage, which to date is still far from the targets set by the PNPV'17-'19 in adults at risk for disease.The purpose of this study Single-center prospective longitudinal observational cohort study is to verify patients' compliance with the proposed vaccination, the effectiveness of counseling carried out by a multidisciplinary team in the hospital setting., conditionsModule conditions: Herpes Zoster, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 48, type: ESTIMATED, armsInterventionsModule interventions name: Herpes Zoster adjuvanted recombinant vaccine, outcomesModule primaryOutcomes measure: Compliance to vaccination, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fondazione Policlinico Universitario A. Gemelli - UCSC, status: RECRUITING, city: Roma, state: RM, zip: 00168, country: Italy, contacts name: Patrizia Laurenti, MD PHD, role: CONTACT, email: patrizia.laurenti@policlinicogemelli.it, geoPoint lat: 41.89193, lon: 12.51133, hasResults: False
protocolSection identificationModule nctId: NCT06334848, orgStudyIdInfo id: TOT versus mini sling, briefTitle: Efficacy of Mini Sling Versus Transobturator Tape in Surgical Management of Women With Stress Urinary Incontinence, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-09, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Ain Shams University, class: OTHER, descriptionModule briefSummary: To compare the efficacy of mini sling against Transobturator tape for surgical management of women with stress urinary incontinence., conditionsModule conditions: Stress Urinary Incontinence, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 42, type: ESTIMATED, armsInterventionsModule interventions name: transobturator tape, outcomesModule primaryOutcomes measure: Comparing Mini Sling and Transobturator Tape in Surgical Management of Women with Stress Urinary Incontinence regarding incidence of complications, primaryOutcomes measure: Comparing Mini Sling and Transobturator Tape in Surgical Management of Women with Stress Urinary Incontinence regarding postoperative pain, secondaryOutcomes measure: Comparing Mini Sling and Transobturator Tape in Surgical Management of Women with Stress Urinary Incontinence regarding sexual function, eligibilityModule sex: FEMALE, maximumAge: 60 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06334835, orgStudyIdInfo id: 1/23 OSS SDN, briefTitle: Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells., statusModule overallStatus: RECRUITING, startDateStruct date: 2023-04-30, primaryCompletionDateStruct date: 2023-12-31, completionDateStruct date: 2026-05-31, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: IRCCS SYNLAB SDN, class: OTHER, collaborators name: Fondazione Santobono Pausilipon, descriptionModule briefSummary: Long non-coding RNAs (lncRNAs) are a class of biomarkers of crescent interest in the hematologic and oncologic field.They do not encode proteins and can alter gene expression by acting on different steps of regulation, including DNA methylation and chromatin structure. Recent data identified recurrent somatic alterations in genes involved in DNA methylation and post-translational histone modifications in T-ALL, suggesting that epigenetic homeostasis is critically required in restraining tumor development in the T-cell lineage. Further, recent studies showed that the expression levels of specific lncRNAs correlate with the prognosis of patients with Acute Lymphoblastic Leukemia of T-cells (T-ALL). The objectives of this research project are to identify T-ALL-specific lncRNAs to be used as new diagnostic and prognostic biomarkers of disease and to explore their role on chromatin reorganization and transcriptional regulation that may lead to the onset and progression of T-ALL., conditionsModule conditions: Acute Lymphoblastic Leukemia, Pediatric, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: lncRNA signature analyses, outcomesModule primaryOutcomes measure: Evaluation of the expression of selected lncRNAs in pediatric T-ALL patients and cellular models of T-ALL, eligibilityModule sex: ALL, minimumAge: 1 Year, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Irccs Synlab Sdn, status: RECRUITING, city: Naples, zip: 80143, country: Italy, contacts name: Giovanni Smaldone, PhD, role: CONTACT, phone: 3398768331, email: giovanni.smaldone@synlab.it, geoPoint lat: 40.85216, lon: 14.26811, hasResults: False
protocolSection identificationModule nctId: NCT06334809, orgStudyIdInfo id: 028FPO22, briefTitle: INSIDE: Identification of Genomic Screening Pathways in Cancer Patients With DNA Repair Alterations, acronym: INSIDE, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-03-09, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2027-12-31, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Fondazione del Piemonte per l'Oncologia, class: OTHER, descriptionModule briefSummary: 400 patients will be enrolled and divided into 3 cohorts: Cohort A: patients with high risk localized prostate cancer (PC) defined as \>cT3 or PSA \> 20 ng/mL or presence of ECE or SVI at mpMRI;Cohort B: patients with de novo metastatic hormone sensitive prostate cancer (mHSPC);Cohort C: patients with metastatic castration resistant prostate cancer (mCRPC) progressing on a standard treatment., conditionsModule conditions: Prostate Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 400, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Number, type and frequency of DDR and MMR germline/somatic alterations, primaryOutcomes measure: Changes in PSA levels in the 3 cohorts, secondaryOutcomes measure: Number of patient-derived preclinical models, eligibilityModule sex: MALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo, status: RECRUITING, city: Candiolo, state: Turin, zip: 10060, country: Italy, contacts name: Pasquale Rescigno, MD, role: CONTACT, email: pasquale.rescigno@ircc.it, contacts name: Ilaria Buondonno, PhD, role: CONTACT, phone: +390119933393, email: ilaria.buondonno@ircc.it, geoPoint lat: 44.95858, lon: 7.59812, locations facility: AOU San Luigi Gonzaga, status: RECRUITING, city: Orbassano, state: Turin, zip: 10060, country: Italy, contacts name: Francesco Porpiglia, MD, role: CONTACT, geoPoint lat: 45.00547, lon: 7.53813, hasResults: False
protocolSection identificationModule nctId: NCT06334770, orgStudyIdInfo id: FDASuRecD032136, briefTitle: Influence of Roxolid Implant Material on the Implant Stability Implant Stability, acronym: BLX, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-06-15, primaryCompletionDateStruct date: 2022-01-22, completionDateStruct date: 2023-12-12, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Ain Shams University, class: OTHER, descriptionModule briefSummary: Fourteen completely edentulous patients were selected to participate in this study. From the outpatient clinic of Prosthodontic Department, Faculty of Dentistry, Ain Shams University.After fabrication of complete denture for all patients, patients were randomly divided to:Group A: Seven patients were rehabilitated with implant retained maxillary overdenture where four Straumann BLX® implant were inserted opposed by mandibular complete denture.Group B: Seven patients were rehabilitated with implant retained maxillary overdenture where four conventional acid etched implants were inserted opposed by mandibular complete denture.After implant placement using surgical guide, smart peg and ostell device were used to measure the primary stability of the implant then cover screw was placed and after six weeks, secondary stability was measured for both groups.After four months, the second stage started in which exposure of the implant fixtures took place and pick up was carried out.Patients were recalled frequently for post-insertion inspection and adjustment., conditionsModule conditions: Completely Edentulous Patients, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 18, type: ACTUAL, armsInterventionsModule interventions name: Roxolid implants, interventions name: Titanium implants, outcomesModule primaryOutcomes measure: measuring primary at time of surgery, secondaryOutcomes measure: secondary implant stability after 6 weeks, eligibilityModule sex: ALL, minimumAge: 45 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Faculty of Dentistry of Dentistry Ainshams Univeristy, city: Cairo, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06334757, orgStudyIdInfo id: HLX10IIT22, briefTitle: Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-05-08, primaryCompletionDateStruct date: 2024-08-31, completionDateStruct date: 2025-06-30, studyFirstPostDateStruct date: 2024-03-28, lastUpdatePostDateStruct date: 2024-03-28, sponsorCollaboratorsModule leadSponsor name: Henan Cancer Hospital, class: OTHER_GOV, descriptionModule briefSummary: The purpose of this study is to evaluate the efficacy and safety of Serplulimab Plus Bevacizumab and chemotherapy in TKI-resistant EGFR-mutated non-squamous NSCLC Chinese patients., conditionsModule conditions: Non-Squamous Non-Small Cell Lung Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 46, type: ESTIMATED, armsInterventionsModule interventions name: Serplulimab, interventions name: Bevacizumab Biosimilar HLX04, interventions name: Pemetrexed, interventions name: Carboplatin, outcomesModule primaryOutcomes measure: ORR(Overall Response Rate), secondaryOutcomes measure: PFS(Progression Free Survival), secondaryOutcomes measure: OS(Overall Survival), secondaryOutcomes measure: AE(Adverse Event), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Henan Cancer Hospital, status: RECRUITING, city: Zhengzhou, state: Henan, zip: 450003, country: China, contacts name: zhen he, role: CONTACT, phone: 13523530961, geoPoint lat: 34.75778, lon: 113.64861, hasResults: False